Analysts have slashed hundreds of millions of dollars off their 2022 sales forecasts for three Canadian cannabis producers, reflecting an increasingly competitive landscape across the adult-use industry, falling overall prices and poor execution by some executive teams.
Edmonton, Alberta-based Aurora Cannabis sent its largest ever shipment of medical marijuana to the fast-expanding Israeli market, the company announced Tuesday.
Canadian cannabis producer Organigram increased its investment in cannabinoid biosynthesis company Hyasynth Biologicals, the companies announced.
Auxly Cannabis gained more share of Canada’s recreational marijuana market than any of its competitors in 2021, and the Toronto-based licensed producer has its sights set on even more.
Two Florida residents face charges related to their participation in an alleged insider trading scheme that generated roughly $4 million in profits in 2019, including approximately $2.2 million from trades of then-Canadian cannabis producer Aphria.
German pharmaceutical manufacturer Dermapharm Holding SE has struck a deal to buy C3 Cannabinoid Compound Co. GmbH from Canadian cannabis producer Canopy Growth.
Maltese lawmakers approved a landmark bill that decriminalizes some quantities of recreational cannabis, regulates home cultivation and permits nonprofit cannabis clubs in the European Union country.
Canadian cannabis producer Hexo is shaking up its board and promising a renewed focus on consumers after the struggling Quebec-based company lost 117 million Canadian dollars ($91 million) in its first quarter of fiscal 2022.
Shares of The Valens Co. commenced trading on the Nasdaq Capital Market on Thursday, the Kelowna, British Columbia-based business announced in a news release.
A disparate group of countries, businesses and organizations is calling on the Canadian government to remove nontariff barriers effectively blocking commercial imports of medical marijuana, even as some local players say the ban is needed to protect squeezed domestic cultivators.
Pure Sunfarms knew the time would come when the British Columbia-based producer would need to expand cultivation at its massive cannabis greenhouse, even as some competitors were closing and selling facilities for pennies on the dollar.
In an interview with MJBizDaily, CEO Mandesh Dosanjh explained why that time is now.
Emerald Health Therapeutics plans to exit Canada’s recreational and medical cannabis sectors after racking up more than 200 million Canadian dollars ($156 million) in losses since its inception
